Inside Vertex’s quest to develop new non-opioid painkillers

Success of any kind from Vertex would upend a long history of pharma failure in pursuit of non-opioid pain treatments.

December 11, 2023 Check out STAT+

Sponsored By

Sandy Huffaker for STAT STAT+ | Inside Vertex's decades-long quest to develop a new class of non-opioid painkillers Vertex is about to announce results from late-stage trials of a drug that precisely blocks pain-sensing neurons from signaling the brain. By Jonathan Wosen STAT+ | After sickle-cell screwups, Bluebird Bio's only option might be a company sale The consequences of strategic blunders — arguably, self-inflicted — could imperil Bluebird's independence, perhaps even its survival. By Adam Feuerstein STAT+ | The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds Topping the list was AbbVie's Humira, for which spending rose $386 million after the list price rose 7.1%, although the net price rose 1.9% By Ed Silverman Jake Belcher for STAT STAT+ | A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk STAT sat down with Boger to discuss how Vertex began working in sickle cell disease, what he thinks the future holds for biotech, and more. By Allison DeAngelis STAT+ | NEJM aims to hold AI to account with new publication The New England Journal of Medicine is launching NEJM AI, an online-only publication focused on artificial intelligence in clinical medicine. By Casey Ross STAT+ | GE HealthCare CEO named chair of AdvaMed as device lobby forms new imaging division AdvaMed has named GE HealthCare CEO Peter Arduini as its new chair. The medical device lobby also announced a new medical imaging division. By Lizzy Lawrence Adobe Opinion: U.S. medical schools aren't teaching future doctors about 7.4 million of their patients There are 7.4 million Americans with intellectual and developmental disabilities. But doctors are often uncomfortable treating them. By Romila Santra

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser